IGF-1 LR3
A modified, longer-acting version of IGF-1 researched for muscle growth signaling, protein synthesis, and recovery.
What It Is
IGF-1 LR3 (Insulin-like Growth Factor-1 Long Arg3) is a modified version of IGF-1 designed to remain active in the body longer than the naturally occurring form. IGF-1 is a key growth and repair signal involved in muscle development, protein synthesis, cellular growth, and tissue recovery.
IGF-1 LR3 works primarily through the IGF-1 receptor, activating signaling pathways involved in cellular growth and nutrient utilization — in muscle tissue specifically, research has focused on protein synthesis, glucose and amino-acid uptake, muscle-cell growth, and tissue repair. It is considered a more advanced research compound than typical recovery peptides.
Who May Benefit
- Muscle hypertrophy research
- Lean-mass development
- Muscle recovery
- Protein synthesis research
- Exercise adaptation
- Tissue repair
- Performance and body composition
What to Expect
IGF-1 LR3 is generally researched as a consistent protocol over several weeks rather than an immediate performance compound, with interest centered on muscle growth signaling, protein synthesis, nutrient utilization, recovery, and tissue regeneration.
Because IGF-1 influences multiple tissues and metabolic pathways, individual response varies and increasing the dose does not necessarily translate into proportionally better results.
What to Pair It With
Reconstitution
Suggested Research Dosing Strategy
Administration Notes
Subcutaneous or intramuscular administration may be used. Localized administration near the muscle being researched is sometimes incorporated, though it does not guarantee a localized effect.
Post-workout administration alongside protein and a small amount of carbohydrate is a common approach; morning administration is sometimes used on non-training days.
Blood glucose should be monitored given IGF-1’s role in glucose metabolism. Watch for changes in appetite, joint discomfort, or swelling.
Research Considerations
IGF-1 LR3 works further downstream in the GH axis than GHRH/GHRP peptides — rather than stimulating the pituitary, it acts directly on IGF-1 signaling, which is part of why it is considered a more powerful and broadly active compound.
The long-term safety and efficacy of IGF-1 LR3 specifically have not been established through robust human clinical research, and its broad biological activity across tissues is why it deserves more caution than recovery-focused peptides.
Have a specific question about IGF-1 LR3? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.